one8zero8 LLC Buys New Position in Encompass Health Co. (NYSE:EHC)

one8zero8 LLC bought a new position in Encompass Health Co. (NYSE:EHC - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,265 shares of the company's stock, valued at approximately $394,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. CIBC Asset Management Inc lifted its position in Encompass Health by 3.5% in the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company's stock worth $286,000 after purchasing an additional 100 shares during the period. Miracle Mile Advisors LLC raised its stake in Encompass Health by 3.0% during the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company's stock worth $354,000 after acquiring an additional 112 shares in the last quarter. US Bancorp DE raised its stake in Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company's stock worth $127,000 after acquiring an additional 121 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after acquiring an additional 137 shares in the last quarter. Finally, SPC Financial Inc. raised its stake in Encompass Health by 0.3% during the fourth quarter. SPC Financial Inc. now owns 45,077 shares of the company's stock worth $4,163,000 after acquiring an additional 154 shares in the last quarter. 97.25% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.10% of the company's stock.

Remove Ads

Encompass Health Trading Down 0.2 %

EHC traded down $0.23 during midday trading on Thursday, reaching $99.13. 565,615 shares of the company were exchanged, compared to its average volume of 631,575. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. Encompass Health Co. has a one year low of $76.11 and a one year high of $104.55. The stock has a market capitalization of $9.98 billion, a P/E ratio of 22.23, a PEG ratio of 2.31 and a beta of 0.92. The stock's 50-day simple moving average is $97.73 and its 200 day simple moving average is $97.06.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health's dividend payout ratio (DPR) is currently 15.25%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on EHC. Royal Bank of Canada reiterated an "outperform" rating and set a $110.00 price objective on shares of Encompass Health in a research note on Tuesday, February 11th. KeyCorp increased their price objective on Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. StockNews.com upgraded Encompass Health from a "hold" rating to a "buy" rating in a research note on Saturday, February 15th. William Blair restated an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Finally, Barclays raised their target price on Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.